BIG
CRNX

Brooklyn Investment Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Brooklyn Investment Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,890
Closed -$280K – 1887
2025
Q4 		$280K Buy
+5,890
New +$262K 0.01% 1102
2025
Q3 		– Sell
-37
Closed -$1.06K – 1124
2025
Q2 		$1.06K Buy
37
+7
+23% +$216 ﹤0.01% 2919
2025
Q1 		$1.01K Sell
30
-34
-53% -$1.27K ﹤0.01% 2347
2024
Q4 		$3.27K Buy
+64
New +$3.58K ﹤0.01% 1340

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Brooklyn Investment Group's CRNX Position: Q1 2026 in Review

Brooklyn Investment Group sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 5,890 shares — an estimated $280K sold.

Brooklyn Investment Group first reported a position in CRNX in Q4 2024 and held it in 4 quarters. The position peaked at $280K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Brooklyn Investment Group reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Brooklyn Investment Group sold 5,890 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $280K.
  • Brooklyn Investment Group first reported a position in Crinetics Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Brooklyn Investment Group's Crinetics Pharmaceuticals position peaked at $280K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.